Itraconazole vs Terbinafun
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have all the information needed for a thorough, well-sourced comparison. Let me compile the answer:
Itraconazole vs Terbinafine: A Comprehensive Comparison
1. Drug Class & Mechanism of Action
| Feature | Itraconazole | Terbinafine |
|---|---|---|
| Drug class | Triazole (azole antifungal) | Allylamine |
| Target enzyme | Lanosterol 14α-demethylase (CYP51) | Squalene epoxidase |
| Effect on ergosterol | Inhibits ergosterol synthesis; causes accumulation of toxic sterol intermediates | Inhibits squalene → ergosterol conversion; also causes squalene accumulation (toxic to fungus) |
| Fungistatic or fungicidal | Fungistatic | Fungicidal (against dermatophytes) |
Itraconazole blocks ergosterol synthesis at the demethylation step, while terbinafine acts earlier in the pathway at squalene epoxidase - making it fungicidal rather than merely fungistatic against dermatophytes (Fitzpatrick's Dermatology, p.3467).
2. Pharmacokinetics
| Parameter | Itraconazole | Terbinafine |
|---|---|---|
| Oral absorption | Erratic; requires acidic gastric pH; capsule form variable; solution better on empty stomach | Well absorbed; not affected by food; ~40% bioavailability due to first-pass metabolism |
| Protein binding | Highly protein bound | Highly protein bound |
| t½ | ~30-40 h at steady state (steady state reached in 4 days; hydroxy-itraconazole takes 7 days) | Initial ~12 h; extends to 200-400 h at steady state |
| Distribution | Distributes to most tissues; poor CNS/CSF penetration | Accumulates in skin, nails, fat; poor penetration beyond skin/nails |
| Elimination | Hepatic CYP3A4 metabolism | Hepatic (CYP2D6); excreted mainly in urine |
| Loading dose needed? | Yes (due to delayed steady state) | Not typically required |
- Goodman & Gilman's, p.1224; Medical Microbiology 9e, block 6
3. Spectrum of Activity
| Organism | Itraconazole | Terbinafine |
|---|---|---|
| Dermatophytes (Trichophyton, Microsporum, Epidermophyton) | Active | Active (superior - fungicidal) |
| Candida spp. | Active (including candidal onychomycosis) | Less active |
| Malassezia furfur | Active | Less active |
| Molds (Aspergillus) | Active | Limited systemic activity |
| Endemic dimorphic fungi (Histoplasma, Blastomyces, Coccidioides) | Active - first-line for mild-moderate disease | Not preferred (poor tissue penetration beyond skin) |
| Mucorales | Active | Not active |
| Sporothrix, Phaeohyphomycosis | Active | Limited |
Terbinafine's fungicidal activity against T. rubrum and T. mentagrophytes is superior to both griseofulvin and itraconazole (Fitzpatrick's Dermatology). However, it does not work well against non-dermatophyte molds or Candida causing onychomycosis.
4. Clinical Uses
| Indication | Preferred Agent | Notes |
|---|---|---|
| Dermatophyte onychomycosis | Terbinafine (first-line) | 250 mg/day x 6 wk (fingernails) or 12 wk (toenails). More effective than itraconazole for dermatophytes. |
| Candidal onychomycosis | Itraconazole | Itraconazole is more effective for candidal nail infection |
| Tinea capitis | Terbinafine preferred for T. tonsurans (US); itraconazole also effective | Griseofulvin historically used but terbinafine now preferred |
| Tinea corporis/cruris/pedis | Either (topical preferred first) | Both effective orally when topical fails |
| Tinea versicolor (widespread) | Itraconazole | Terbinafine less active against Malassezia |
| Histoplasmosis (mild-moderate) | Itraconazole (drug of choice) | Also for blastomycosis, coccidioidomycosis |
| Aspergillosis | Itraconazole (older option; voriconazole now preferred) | Terbinafine not used |
| Oropharyngeal candidiasis | Itraconazole | Terbinafine not effective |
| Mucocutaneous candidiasis | Itraconazole | - |
| Sporotrichosis | Itraconazole | - |
- Harrison's 22E (2025), p.1735; Goodman & Gilman's, block 20
5. Drug Interactions
Itraconazole
- Potent CYP3A4 inhibitor (itraconazole = ketoconazole in potency - the strongest among azoles)
- Also inhibits P-glycoprotein
- Rifampin reduces itraconazole levels (enzyme inducer - avoid this combination)
- Causes accumulation of statins, cyclosporine, tacrolimus, digoxin, warfarin, antiretrovirals, benzodiazepines, and many others
- Katzung's Basic & Clinical Pharmacology, 16e
Terbinafine
- CYP2D6 inhibitor - increases levels of β-blockers, TCAs, SSRIs, MAO inhibitors, type 1C antiarrhythmics
- Rifampin decreases terbinafine levels
- Cimetidine increases terbinafine levels
- Relatively contraindicated with cyclosporine and rifampin
- Much fewer serious drug interactions compared to itraconazole
- Dermatology 5e (Elsevier), block 28; Goodman & Gilman's
6. Adverse Effects
| Effect | Itraconazole | Terbinafine |
|---|---|---|
| Hepatotoxicity | Yes (monitor LFTs) | Rare but can be fatal; avoid in hepatic/renal impairment |
| Cardiac toxicity | Yes - CHF risk (negative inotrope; contraindicated in heart failure) | Not reported |
| GI disturbance | Common (nausea, diarrhea) | Low incidence |
| Headache | Occasional | Low incidence |
| Taste disturbance | Occasional | Can cause loss of taste (ageusia) - rare but notable |
| Stevens-Johnson / TEN | Rare | Very rare |
| Neutropenia | Rare | Very rare (severe) |
| Pregnancy | Category C; avoid if possible | Avoid during pregnancy |
| Renal/hepatic failure | Reduce dose / avoid | Avoid in moderate-severe renal or hepatic impairment |
7. Dosing & Formulations
| Itraconazole | Terbinafine | |
|---|---|---|
| Oral forms | Capsule, oral solution, IV | Tablet (250 mg), topical cream/spray |
| Standard adult dose | 200 mg OD or 100-200 mg BD (indication-dependent) | 250 mg OD |
| Pulse dosing | 200 mg BD x 1 week/month x 3 months (onychomycosis) | 500 mg/day x 1 week/month x 3 months (used in some protocols) |
| Bioavailability formulation note | SUBA-itraconazole (super-bioavailability) recently FDA-approved for improved absorption | Standard tablets have consistent absorption |
8. Head-to-Head: Onychomycosis (Key Clinical Battleground)
This is where the two drugs are most commonly compared:
- Terbinafine is superior for dermatophyte onychomycosis - higher mycological cure rates and shorter treatment duration (Goodman & Gilman's, p.1224; Lippincott Reviews Pharmacology)
- Itraconazole is preferred for candidal onychomycosis and remains in nail tissue for 6-9 months after therapy ends
- Tinea pedis: Topical terbinafine or azole is first-line; both drugs work systemically
- Tinea capitis caused by T. tonsurans: Terbinafine preferred over itraconazole in the US
9. Quick Summary
| Feature | Itraconazole | Terbinafine |
|---|---|---|
| Class | Triazole | Allylamine |
| Action | Fungistatic | Fungicidal (dermatophytes) |
| Best for | Systemic mycoses, candidal/mold infections, endemic fungi | Dermatophyte infections, nail/skin |
| Drug interactions | Major (CYP3A4 + P-gp inhibitor) | Moderate (CYP2D6 inhibitor only) |
| Cardiac risk | Yes (avoid in CHF) | No |
| Hepatotoxicity | Yes | Rare but severe |
| Onychomycosis | Effective (especially Candida) | First-line (dermatophytes) |
| Systemic mycoses | Yes (histoplasma, blastomyces, etc.) | No |
Bottom line: Choose terbinafine when treating dermatophyte nail/skin infections (better fungicidal activity, fewer interactions, simpler monitoring). Choose itraconazole when the organism is Candida, Malassezia, or a systemic/endemic fungus, or when broader spectrum is needed - but be vigilant about drug interactions and cardiac contraindications.
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics | Harrison's Principles of Internal Medicine 22E (2025) | Fitzpatrick's Dermatology, Vol. 1-2 | Katzung's Basic & Clinical Pharmacology, 16e | Lippincott Illustrated Reviews: Pharmacology
This is a shared conversation. Sign in to Orris to start your own chat.